Diabetic drug markets in tumultuous turmoil.

A tremendous change seems to explode in the diabetic drug markets by the recent article on the cardiovascular disease risk of Avandia, an diabetic drug for the patients with type II diabetes, published in the New England Journal of Medicine.

Avandia, a derivative of Thiazolidinediones (TZD) as a sensitivity enhancing mode against the insulin resistance, has achieved yearly 40 billion won of...